Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach

Research output: Contribution to journalJournal articleResearchpeer-review

The role of health-related economy is crucial due to the finite healthcare resources. Intravenous (i.v.) regimes Nordic FLOX and Nordic FLIRI, and the partly oral alternatives XELIRI and XELOX are four commonly used chemotherapies in the first-line treatment of advanced colorectal cancer (CRC) in the Scandinavian countries, all with different costs.
Original languageEnglish
JournalActa Odontologica Scandinavica
Volume51
Issue number7
Pages (from-to)840-8
Number of pages9
ISSN0001-6357
DOIs
Publication statusPublished - Sep 2012
Externally publishedYes

ID: 45707850